Cytokine Release Syndrome (CRS) Risk Monitoring in Cellular Immunotherapies
Cytokine Release Syndrome is a major safety concern in CAR-T, TCR, and NK cell therapy programs. Accelevir offers GLP-compliant CRS monitoring assays to detect early inflammatory cytokine elevations and assess patient risk prior to and during treatment.
Technical Capabilities:
- Luminex/ELISA for IL-6, IFN-γ, TNF-α, IL-2, IL-10, and other CRS biomarkers.
- Preclinical safety screening for CRS potential.
- Longitudinal cytokine tracking during clinical trials.
- Integrated immune cell activation profiling.
Why Partner with Accelevir:
- CRS monitoring experience across multiple CAR-T and NK platforms.
- CLIA-certified assays for regulated clinical testing.